Development of GPIIb/IIIa antagonists as antithrombotic drugs

Thrombosis represents a major target for development of drugs to prevent and treat a variety of cardiovascular and cerebrovascular diseases, which are the leading cause of morbidity and mortality in the Western world. This review by Andy Nichols and colleagues focuses on a central process in thrombo...

Full description

Saved in:

Bibliographic Details
Published in:	Trends in pharmacological sciences (Regular ed.) Vol. 13; no. 11; p. 413
Main Authors:	Nichols, A J, Ruffolo, Jr, R R, Huffman, W F, Poste, G, Samanen, J
Format:	Journal Article
Language:	English
Published:	England 01-11-1992
Subjects:	Amino Acid Sequence Fibrinolytic Agents - pharmacology Humans Molecular Sequence Data Oligopeptides - pharmacology Oligopeptides - physiology Platelet Aggregation - physiology Platelet Aggregation Inhibitors - pharmacology Platelet Membrane Glycoproteins - antagonists & inhibitors
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Thrombosis represents a major target for development of drugs to prevent and treat a variety of cardiovascular and cerebrovascular diseases, which are the leading cause of morbidity and mortality in the Western world. This review by Andy Nichols and colleagues focuses on a central process in thrombosis, namely platelet aggregation, and how it can be inhibited by antagonists of the adhesion molecule GPIIb/IIIa. Successful and future therapeutic applications of GPIIb/IIIa antagonists, and their pharmacology, are considered in detail.
ISSN:	0165-6147
DOI:	10.1016/0165-6147(92)90126-Q